Contrasting features of urea cycle disorders in human patients and knockout mouse models

被引:57
作者
Deignan, Joshua L. [1 ,5 ]
Cederbaum, Stephen D. [2 ,3 ,4 ,5 ]
Grody, Wayne W. [1 ,3 ,4 ,5 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Mental Retardat Res Ctr, Los Angeles, CA 90095 USA
关键词
urea; hyperammonemia; knockout; N-acetylglutamate synthase; carbamyl phosphate synthetase I; ornithine transcarbamylase; argininosuccinate synthetase; argininosuccinate lyase; arginase;
D O I
10.1016/j.ymgme.2007.08.123
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The urea cycle exists for the removal of excess nitrogen from the body. Six separate enzymes comprise the urea cycle, and a deficiency in any one of them causes a urea cycle disorder (UCD) in humans. Arginase is the only urea cycle enzyme with an alternate isoform, though no known human disorder currently exists due to a deficiency in the second isoform. While all of the UCDs usually present with hyperammonemia in the first few days to months of life, most disorders are distinguished by a characteristic profile of plasma amino acid alterations that can be utilized for diagnosis. While enzyme assay is possible, an analysis of the underlying mutation is preferable for an accurate diagnosis. Mouse models for each of the urea cycle disorders exist (with the exception of NAGS deficiency), and for almost all of them, their clinical and biochemical phenotypes rather closely resemble the phenotypes seen in human patients. Consequently, all of the current mouse models are highly useful for future research into novel pharmacological and dietary treatments and gene therapy protocols for the management of urea cycle disorders. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 95 条
[1]
ADCOCK MW, 1984, J BIOL CHEM, V259, P3471
[2]
Molecular basis of hyperargininemia: Structure-function consequences of mutations in human liver arginase [J].
Ash, DE ;
Scolnick, LR ;
Kanyo, ZF ;
Vockley, JG ;
Cederbaum, SD ;
Christianson, DW .
MOLECULAR GENETICS AND METABOLISM, 1998, 64 (04) :243-249
[3]
BACHMANN C, 1982, ADV EXP MED BIOL, V153, P39
[4]
Batshaw ML, 1995, GENE THER, V2, P743
[5]
Alternative pathway therapy for urea cycle disorders: Twenty years later [J].
Batshaw, ML ;
MacArthur, RB ;
Tuchman, M .
JOURNAL OF PEDIATRICS, 2001, 138 (01) :S46-S54
[6]
BEAUDET AL, 1986, ADV HUM GENET, V15, P161
[7]
Brusilow S W, 1996, Adv Pediatr, V43, P127
[8]
Late onset N-acetylglutamate synthase deficiency caused by hypomorphic alleles [J].
Caldovic, L ;
Morizono, H ;
Panglao, MG ;
Lopez, GY ;
Shi, DS ;
Summar, ML ;
Tuchman, M .
HUMAN MUTATION, 2005, 25 (03) :293-298
[9]
Null mutations in the N-acetylglutamate synthase gene associated with acute neonatal disease and hyperammonemia [J].
Caldovic, L ;
Morizono, H ;
Panglao, MG ;
Cheng, SF ;
Packman, S ;
Tuchman, M .
HUMAN GENETICS, 2003, 112 (04) :364-368
[10]
Cloning and expression of the human N-acetylglutamate synthase gene [J].
Caldovic, L ;
Morizono, H ;
Panglao, MG ;
Gallegos, R ;
Yu, XL ;
Shi, DS ;
Malamy, MH ;
Allewell, NM ;
Tuchman, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 299 (04) :581-586